The Medicines Manufacturing Innovation Centre partners with Pfizer to transform the formulation of oral solid dosage medicines
25 Feb 2021
CPI has today announced an agreement with Pfizer, making it the newest partner of the Medicines Manufacturing Innovation Centre collaboration. The partnership will enable the Centre to draw upon Pfizer’s expertise within the pharmaceutical sector to help address key challenges and maximise efficiency within the medicines supply chain.
The Medicines Manufacturing Innovation Centre is a collaboration between CPI, the University of Strathclyde and founding industry partners GSK and AstraZeneca, with funding provided by Scottish Enterprise and UK Research and Innovation. The Centre aims to advance emergent and disruptive technologies through a series of flagship ‘Grand Challenge’ projects to increase productivity and patient outcomes in the pharmaceutical industry.
The new partnership with Pfizer will focus on Grand Challenge 1, which aims to develop an innovative continuous direct compression (CDC) platform enabling oral solid dosage medicines to be formulated more robustly and efficiently. The CDC platform will feature a digital twin and data predictor model to allow for the modelling of processes in a digital space. This capability will improve efficiency and significantly cut down the quantity of starting materials needed to optimise formulations with the aim of enabling companies to ultimately develop formulations faster and at reduced cost.
As a partner in the Medicines Manufacturing Innovation Centre collaboration, Pfizer will be providing data, expert skill and knowledge of continuous mixing technology. Pfizer’s contributions to Grand Challenge 1 will aim to minimise costs and significantly reduce risk by providing vital technical expertise for further development of the digital twin and data predictor model for the CDC platform.
Dave Tudor, Managing Director at the Medicines Manufacturing Innovation Centre, said: “We are extremely proud to be working with Pfizer and look forward to drawing on its wealth of expertise in the pharmaceutical industry. This partnership will help to further develop the CDC platform as part of Grand Challenge 1, leading to reduced materials requirements and lower costs for the end-user.”
Brian Henry, Vice President, Drug Product Design, at Pfizer, said: “We are excited to begin our partnership with the Medicines Manufacturing Innovation Centre to support the delivery of Grand Challenge 1. Through the support of Pfizer’s Emerging Science Fund, we believe we can utilize our collective knowledge to build predictive models for continuous tablet manufacturing, with the goal of enhancing our ability to accelerate the drug development process and help deliver breakthroughs that change patients’ lives.”
About the Medicines Manufacturing Innovation Centre
The Medicines Manufacturing Innovation Centre was established by a collaboration between CPI, the University of Strathclyde, UK Research and Innovation, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
The consortium aims to develop the medicines manufacturing processes of the future, enabling a more agile, responsive medicines supply chain through improved manufacturing processes. It will enable new and disruptive technologies to be proven at scale in a GMP environment. This will allow the rapid adoption of next-generation processes that reduce risk, cut costs and save time, enabling a healthier society and a robust UK economy.
With a collaborative innovation culture and state-of-the-art facilities, the Centre will enable industry, academia, healthcare providers and regulators to work collaboratively in order to address challenges and maximise technology opportunities within the medicines supply chain.
The Centre is already delivering two ’Grand Challenges’. The first is exploring how oral solid dosage medicines can be produced more robustly and efficiently utilising continuous direct compression. The second is focussed on how these medicines can then be delivered to patients with minimal waste and maximum speed, using Just in Time manufacture and release capabilities.
CPI works with partners to translate inventions into products and processes that enhance health and wellbeing, protect and improve our environment and increase productivity across industries.
With a deep understanding of technology fore-sighting, innovation processes and funding, outstanding technical expertise and industry-relevant assets, we enable the accelerated development of transformational products and processes that have the potential to disrupt and revolutionise markets. We also engage in incremental technological innovation that allows established products and processes to be optimised for better performance and efficient manufacture.
Through the breadth of our technology platforms, we support our partners across many diverse markets, including pharmaceuticals, speciality chemicals, food and drink, electronics and transportation.
About the University of Strathclyde
For more than 200 years, the University of Strathclyde has been meeting the needs of students, employers, industry and wider society through world-class research, teaching, innovation and enterprise. Today, as a leading international technological University, Strathclyde works side-by-side with business, industry, government and the public sector, to improve health, safeguard the future of energy supplies, set new manufacturing standards, and pioneer technologies. Its entrepreneurial environment makes Strathclyde the partner of choice for growing numbers of organisations across the world. It has been recognised through the award of Times Higher Education UK Business School of the Year, Entrepreneurial University of the Year, and University of the Year.
About Scottish Enterprise
Scottish Enterprise is Scotland’s national economic development agency. We’re committed to growing the Scottish economy for the benefit of all, helping create more quality jobs and a brighter future for every region.
Follow us on Facebook at http://www.facebook.com/scottishenterprise
UK Research and Innovation
This project has been funded by the Industrial Strategy Challenge Fund, part of the government’s modern Industrial Strategy. The fund is delivered by UK Research and Innovation.
The Industrial Strategy Challenge Fund brings together the UK’s world-leading research with business to meet our time’s major industrial and societal challenges. It provides funding and support to UK businesses and researchers, part of the government’s £4.7 billion increase in research and development over the next four years. It plays a central role in the government’s modern Industrial Strategy.
UK Research and Innovation is a new organisation that brings together the UK Research Councils, Innovate UK and Research England into a single organisation to create the best environment for research and innovation to flourish. The vision is to ensure the UK maintains its world-leading position in research and innovation. For more information visit www.ukri.org
Let’s innovate together
To find out more about how we can work together, please enter your details below.